158 related articles for article (PubMed ID: 23266941)
1. Lack of correlation between angiogenic cytokines and serum insulin-like growth factor-1 in patients with multiple myeloma.
Pappa CA; Tsirakis G; Psarakis FE; Kolovou A; Tsigaridaki M; Stafylaki D; Sfiridaki K; Alexandrakis MG
Med Oncol; 2013 Mar; 30(1):363. PubMed ID: 23266941
[TBL] [Abstract][Full Text] [Related]
2. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
4. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
5. Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.
Pappa CA; Alexandrakis MG; Boula A; Psarakis FE; Kolovou A; Bantouna V; Stavroulaki E; Tsirakis G
Hematol Oncol; 2013 Dec; 31(4):201-5. PubMed ID: 23576184
[TBL] [Abstract][Full Text] [Related]
6. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma.
Alexandrakis MG; Goulidaki N; Pappa CA; Boula A; Psarakis F; Neonakis I; Tsirakis G
Pathol Oncol Res; 2015 Sep; 21(4):929-34. PubMed ID: 25743259
[TBL] [Abstract][Full Text] [Related]
8. Increased serum levels of MIP-1alpha correlate with bone disease and angiogenic cytokines in patients with multiple myeloma.
Tsirakis G; Roussou P; Pappa CA; Kolovou A; Vasilokonstantaki C; Miminas I; Kyriakaki S; Alegakis A; Alexandrakis MG
Med Oncol; 2014 Jan; 31(1):778. PubMed ID: 24277416
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma.
Alexandrakis MG; Passam FJ; Ganotakis E; Dafnis E; Dambaki C; Konsolas J; Kyriakou DS; Stathopoulos E
Clin Chem Lab Med; 2004; 42(10):1122-6. PubMed ID: 15552270
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma.
Iwasaki T; Hamano T; Ogata A; Hashimoto N; Kitano M; Kakishita E
Br J Haematol; 2002 Mar; 116(4):796-802. PubMed ID: 11886383
[TBL] [Abstract][Full Text] [Related]
13. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.
Sfiridaki K; Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Sakellaris G; Kontakis G; Alexandrakis MG
Mediators Inflamm; 2011; 2011():867576. PubMed ID: 21941412
[TBL] [Abstract][Full Text] [Related]
15. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.
Tsirakis G; Pappa CA; Psarakis FE; Fragioudaki M; Tsioutis C; Stavroulaki E; Boula A; Alexandrakis MG
Med Oncol; 2012 Dec; 29(4):2396-401. PubMed ID: 22403003
[TBL] [Abstract][Full Text] [Related]
16. The Low Expression of IL-37 Involved in Multiple Myeloma - Associated Angiogenesis.
Li ZC; Sun MD; Zheng YQ; Fu HJ
Med Sci Monit; 2016 Nov; 22():4164-4168. PubMed ID: 27807338
[TBL] [Abstract][Full Text] [Related]
17. Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
Alexandrakis MG; Pappa CA; Kokonozaki M; Boula A; Vyzoukaki R; Staphylaki D; Papadopoulou A; Androulakis N; Tsirakis G; Sfiridaki A
Med Oncol; 2015 Mar; 32(3):42. PubMed ID: 25631632
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines.
Alexandrakis MG; Passam FH; Sfiridaki A; Pappa CA; Moschandrea JA; Kandidakis E; Tsirakis G; Kyriakou DS
Int J Biol Markers; 2004; 19(1):52-7. PubMed ID: 15077927
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
Kara IO; Sahin B; Gunesacar R; Unsal C
Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
[TBL] [Abstract][Full Text] [Related]
20. The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.
Tsirakis G; Pappa CA; Kaparou M; Boula A; Katsomitrou V; Xekalou A; Kyriakaki S; Alexandrakis MG
Tumour Biol; 2013 Apr; 34(2):859-64. PubMed ID: 23242610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
